Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Heath

Showing results (411-420 of 425) with videos related to

Pageof 43
Sort By:
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
Medical Mycology|March 7, 2023
Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS studyAislinn Cook, Laura Ferreras-Antolin, Bethou Adhisivam, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled TrialPaul T Heath, Eva P Galiza, David Neil Baxter, et al.
Blood|October 8, 2010
X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the diseaseClaire Booth, Kimberly C Gilmour, Paul Veys, et al.
Nature Communications|May 10, 2024
Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countriesBiljana Kakaraskoska Boceska, Tuba Vilken, Basil Britto Xavier, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Clinical and Experimental Immunology|July 12, 2013
The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012J D M Edgar, M Buckland, D Guzman, et al.
Antibiotics (Basel, Switzerland)|May 27, 2023
Challenges in the Implementation of the NeoOBS Study, a Global Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of Neonatal Sepsis in the Hospital SettingAmy Riddell, Aislinn Cook, Nathalie Khavessian, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Pageof 43

Showing results (411-420 of 425) with videos related to

Sort By:
Pageof 43
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
Medical Mycology|March 7, 2023
Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS studyAislinn Cook, Laura Ferreras-Antolin, Bethou Adhisivam, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled TrialPaul T Heath, Eva P Galiza, David Neil Baxter, et al.
Blood|October 8, 2010
X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the diseaseClaire Booth, Kimberly C Gilmour, Paul Veys, et al.
Nature Communications|May 10, 2024
Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countriesBiljana Kakaraskoska Boceska, Tuba Vilken, Basil Britto Xavier, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Clinical and Experimental Immunology|July 12, 2013
The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012J D M Edgar, M Buckland, D Guzman, et al.
Antibiotics (Basel, Switzerland)|May 27, 2023
Challenges in the Implementation of the NeoOBS Study, a Global Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of Neonatal Sepsis in the Hospital SettingAmy Riddell, Aislinn Cook, Nathalie Khavessian, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Pageof 43